A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

Status Authorised, recruitment pending · 1 EU/EEA countries · 1 sites · Protocol CN0140003

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other

Status Authorised, recruitment pending

Participants planned 12

Countries 1

Sites 1

Neuropsychiatric indications and potentially other conditions

Sponsor: Bristol-Myers Squibb Services Unlimited Company
Participant type: Healthy volunteers
Age range: 18-64 years
Gender: Male and Female
Therapeutic area: Psychiatry and Psychology [F] - Behavior and Behavior Mechanisms [F01], Psychiatry and Psychology [F] - Mental Disorders [F03], Diseases [C] - Nervous System Diseases [C10]
Decision date (initial): 2026-05-22
Transition trial: No
Low-intervention: No
Rare-disease indication: No
Vulnerable population: No

CTIS Part I — objectives, methods, condition coding

Neuropsychiatric indications and potentially other conditions

Version	Level	Code	Term	System organ class
21.0	LLT	10013202	Disorder central nervous system	10029205

Sponsor organisations, regulatory contacts, third parties

Sponsor organisation: Bristol-Myers Squibb Services Unlimited Company
Address: Plaza 254, Blanchardstown Corporate Park 2 Blanchardstown Corporate Park 2
City: Dublin 15
Postcode: D15 T867
Country: Ireland

1 EU/EEA country · 1 investigational sites

Country	MS status	Planned subjects	Sites
Belgium	Authorised, recruitment pending	12	1
Rest of world	—	0	—

1 site · Authorised, recruitment pending

UZ Leuven

NA, Herestraat 49, 3000, Leuven

1 submissions — initial application plus substantial / non-substantial modifications

#	Type	Code	Submitted	Reference MS	Conclusion	Decision date
1	INITIAL	IN	2026-04-08	Belgium	Acceptable 2026-05-22	2026-05-22